Antiviral treatment guidelines for middle east respiratory syndrome

Rapid Response Team

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Abstract

Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.

Original languageEnglish
Pages (from-to)212-222
Number of pages11
JournalInfection and Chemotherapy
Volume47
Issue number3
DOIs
Publication statusPublished - 2015

Keywords

  • Antiviral
  • Coronavirus
  • MERS
  • Treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antiviral treatment guidelines for middle east respiratory syndrome'. Together they form a unique fingerprint.

Cite this